Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small
molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports …

Massive usage of antiviral compounds during a pandemic creates an ideal ground for
emergence of resistant strains. Remdesivir, a broad-spectrum inhibitor of the viral RNA …

The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not
been reported in patients receiving treatment with the antiviral agent. We present a case of …

We here investigate the impact of antiviral treatments such as remdesivir on intra-host
genomic diversity and emergence of SARS-CoV2 variants in patients with a prolonged …

The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the
rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS …

The use of remdesivir to treat COVID-19 will likely continue before clinical trials are
completed. Due to the lengthening pandemic and evolving nature of the virus, predicting …

New mutations conferring resistance to SARS-CoV-2 therapeutics have important clinical
implications. We describe the first cases of an independently acquired V792I RNA …

Genetic variation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of …

Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved
therapeutics are available. The CoV nsp14 exoribonuclease (ExoN) has complicated …